ClinicalTrials.gg
Active, not recruitingNCT06847724Updated Nov 13, 2026

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

A Phase 3 interventional study of CYB704 and Ocrevus-EU in Relapsing Multiple Sclerosis, sponsored by Sandoz. Active, not recruiting at 41 sites in 8 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing ocrelizumab in Multiple Sclerosis — 3 open to participants now, 14 under way, 8 of them phase 3. ocrelizumab · Multiple Sclerosis.

Enrollment
11th of 27
183 · median 170
Started
2025
with 1 other
Phase 3
13 of 27
2 open now
Primary completion
2026-11
later than 7 of 13 live
Registered
25th of 27
by date

Among the 27 studies testing ocrelizumab in Multiple Sclerosis, this one is the 11th largest by enrollment, is one of 2 that started in 2025, is one of 13 in phase 3, reaches primary completion later than 7 of the 13 other live ones, and was the 25th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

3 of the 27 studies testing ocrelizumab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ocrelizumab

ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing ocrelizumab in Multiple Sclerosis, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if drug CYB704, a proposed biosimilar to Ocrevus, works to treat multiple sclerosis in the same way as the reference product Ocrevus(R).

The main questions it aims to answer are:

  • Is CYB704 distributed in the body in the same way as the reference product (demonstration of pharmacokinetic (PK) similarity)?
  • Does have CYB704 the same treatment effect and side effects as the reference product?

Researchers will compare CYB704 to a Ocrevus (Ocrevus-US and Ocrevus-EU). Participants will:

  • Take drug CYB704 or Ocrevus (Ocrevus-US and Ocrevus-EU)
  • Visit the clinic for at least 15 treatment visits, checkups and tests
  • Will undergo regular magnetic resonance imaging (MRI) examinations
03

Conditions studied

  • Relapsing Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of RMS (relapsing remitting multiple sclerosis (MS) or active secondary progressive MS)
  • Evidence of recent disease activity as defined in study protocol
  • Expanded Disability Status scale score of 0 to 5.5 (inclusive) at screening
  • Neurological stability (no new signs or symptoms referable to Central Nervous System (CNS) within 30 days before both screening and first study treatment

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of primary progressive MS
  • Disease duration of more than 10 years in participants with an Expanded Disability Status Scale (EDSS) ≤2.0 at screening
  • Inability to complete an MRI or to gadolinium administration
  • History of allergic or anaphylactic reactions to ocrelizumab or one of the premedications (methylprednisolone or equivalent , antihistamine, antipyretic)
  • Pregnant participants
  • Current or history of medical conditions as outlined in the study protocol
  • Prohibited medications (current and history) as outlined in the study protocol
  • Abnormal laboratory blood values as outlined in the study protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
183 participants (actual)

Study arms

  • Experimental
    CYB704

    Drug: CYB704 (Ocrelizumab) Patients will be dosed 300 mg on day 1 and day 15. Subsequent dose of 600 mg will be administered 24 weeks after the initial dose.

    Biological: CYB704

  • Active comparator
    Ocrevus-US/Ocrevus-EU

    Drug: Ocrevus-US/Ocrevus-EU Patients will be dosed 300 mg on day 1 and day 15 with Ocrevus-US. Subsequent dose of 600 mg Ocrevus-EU will be administered 24 weeks after the initial dose.

    Biological: Ocrevus-EU · Biological: Ocrevus-US

Interventions

  • BiologicalCYB704

    Intravenous Infusion

    Also known as: Ocrelizumab

  • BiologicalOcrevus-EU

    Intravenous Infusion

    Also known as: Ocrelizumab

  • BiologicalOcrevus-US

    Intravenous Infusion

    Also known as: Ocrelizumab

06

What researchers measure

Primary outcomes

  1. Area under the concentration time curve

    Demonstrate similar PK between Ocrevus and CYB704

    Time frame: Week 1 - 3, week 3 - 25

Secondary outcomes

  1. Area under the plasma concentration versus time curve (AUC)

    Compare PK between Ocrevus and CYB704

    Time frame: Week 1 - 25

  2. Peak Plasma Concentration (Cmax)

    Demonstrate similar PK between Ocrevus and CYB704

    Time frame: Day 1 and Day 15

  3. CD19+ B-cell count

    Compare PD between Ocrevus and CYB704

    Time frame: Up to 48 weeks

  4. Number of new T1 GdE lesions on brain MRI scans

    Compare efficacy between Ocrevus and CYB704

    Time frame: Up to 48 weeks

  5. Number of T1 GdE lesions

    Compare efficacy between Ocrevus and CYB704

    Time frame: Up to 48 weeks

  6. Number of new/enlarging T2 lesions

    Compare efficacy between Ocrevus and CYB704

    Time frame: Up to 48 weeks

  7. Number of combined unique active lesions

    Compare efficacy between Ocrevus and CYB704

    Time frame: Up to 48 weeks

  8. Annualized Relapse Rate

    Compare efficacy between Ocrevus and CYB704

    Time frame: Up to 48 weeks

  9. Treatment emergent Adverse Events and Serious Adverse Events

    Compare safety between Ocrevus and CYB704

    Time frame: Up to 48 weeks

  10. Rate of patients with anti-drug antibodies

    Compare immunogenicity between Ocrevus and CYB704

    Time frame: Up to 48 weeks

07

Study locations

41 sites
  • Sandoz Investigational Site
    Maitland, Florida 32751, United States
  • Sandoz Investigational Site
    Ormond Beach, Florida 32174, United States
  • Sandoz Investigational Site
    Banja Luka, Bosnia and Herzegovina
  • Sandoz Investigational Site
    Bihać, Bosnia and Herzegovina
  • Sandoz Investigational Site 2
    Sarajevo, Bosnia and Herzegovina
  • Sandoz Investigational Site
    Sarajevo, Bosnia and Herzegovina
  • Sandoz Investigational Site
    Pleven, Bulgaria
  • Sandoz Investigational Site 2
    Plovdiv, Bulgaria
  • Sandoz Investigational Site
    Plovdiv, Bulgaria
  • Sandoz Investigational Site 2
    Sofia, Bulgaria
  • Sandoz Investigational Site 3
    Sofia, Bulgaria
  • Sandoz Investigational Site 4
    Sofia, Bulgaria
  • Sandoz Investigational Site 5
    Sofia, Bulgaria
  • Sandoz Investigational Site
    Sofia, Bulgaria
  • Sandoz Investigational Site
    Varaždin, Croatia
  • Sandoz Investigational Site
    Zagreb, Croatia
  • Sandoz Investigational Site
    Rustavi, Georgia
  • Sandoz Investigational Site 2
    Tbilisi, Georgia
  • Sandoz Investigational Site 3
    Tbilisi, Georgia
  • Sandoz Investigational Site 4
    Tbilisi, Georgia
  • Sandoz Investigational Site 5
    Tbilisi, Georgia
  • Sandoz Investigational Site 6
    Tbilisi, Georgia
  • Sandoz Investigational Site 7
    Tbilisi, Georgia
  • Sandoz Investigational Site 8
    Tbilisi, Georgia
  • Sandoz Investigational Site
    Tbilisi, Georgia
  • Sandoz Investigational Site
    Shtip, North Macedonia
  • Sandoz Investigational Site
    Skopje, North Macedonia
  • Sandoz Investigational Site
    Bydgoszcz, Poland
  • Sandoz Investigational Site 2
    Katowice, Poland
  • Sandoz Investigational Site
    Katowice, Poland
  • Sandoz Investigational Site
    Lodz, Poland
  • Sandoz Investigational Site 2
    Lublin, Poland
  • Sandoz Investigational Site
    Lublin, Poland
  • Sandoz Investigational Site
    Nowa Sól, Poland
  • Sandoz Investigational Site 2
    Poznan, Poland
  • Sandoz Investigational Site
    Poznan, Poland
  • Sandoz Investigational Site
    Szczecin, Poland
  • Sandoz Investigational Site
    Warsaw, Poland
  • Sandoz Investigational Site
    Zabrze, Poland
  • Sandoz Investigational Site
    Belgrade, Serbia
  • Sandoz Investigational Site
    Niš, Serbia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Nov 2026, 16 months.

Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 16 months is below that.

Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
Feb 26, 2025
StartActual
Jun 10, 2025
Primary completionActual
Nov 3, 2026
CompletionEst.
May 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and date precision
1 update, last Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Minor edits only
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06847724
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Feb 26, 2025
Start date
Jun 10, 2025
Primary completion
Nov 3, 2026
Completion
May 2027 (estimated)
Last update
Nov 13, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion